Home Newsfeeds Truist Securities Maintains Hold on Array Technologies, Raises Price Target to $22

Truist Securities Maintains Hold on Array Technologies, Raises Price Target to $22

Truist Securities analyst Jordan Levy maintains Array Technologies (NASDAQ:ARRY) with a Hold and raises the price target from $17 to $22.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Truist Securities analyst Jordan Levy maintains Array Technologies (NASDAQ:ARRY) with a Hold and raises the price target from $17 to $22.

News
Tech

Apple Analyst Pretty Sure You Won’t See Physical Buttons On iPhone 15

By Ananya Gairola

January 12, 5:59 AM

Apple Inc.'s (NASDAQ: AAPL) 2023 high-end iPhone 15 series may switch to solid-state buttons from physical ones, and Cirrus Logic Inc. (NASDAQ: CRUS) could be at the center of this change.

AAPL

Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review

By Vandana Singh

May 22, 1:21 PM

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.

NVO

Marijuana Giant Fined $350K In Relation To Worker’s Death, Commission Says Trulieve Failed To Comply With Several Safety Protocols

By Nina Zdinjak

June 14, 9:11 AM

The Massachusetts Cannabis Control Commission (CCC) fined medical marijuana giant Trulieve (OTC:TCNNF) in relation to the death of…

TCNNF

What’s Going On With Concentrix Stock After The Close?

By Adam Eckert

March 29, 5:04 PM

Concentrix Corp (NASDAQ: CNXC) shares are trading lower in Wednesday's after-hours session after the customer experience solutions company reported mixed quarterly results and announced a business combination with Webhelp.

CNXC

Truist Securities Maintains Hold on Array Technologies, Raises Price Target to $22

Related Posts

Apple Analyst Pretty Sure You Won’t See Physical Buttons On iPhone 15

Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review

Marijuana Giant Fined $350K In Relation To Worker’s Death, Commission Says Trulieve Failed To Comply With Several Safety Protocols

What’s Going On With Concentrix Stock After The Close?